Bicycle Therapeutics plc
BCYCHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeBicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. With a market capitalization of $293.9M, it sits in micro-cap territory. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.
Market Cap
$293.9M
Beta
1.55
P/E (TTM)
—
P/E (Fwd)
-1.98
EPS (TTM)
$-3.17
EPS (Fwd)
$-2.13
ROE
-33.8%
ROA
-19.4%
Cash
$559.5M
Total Debt
$15.3M
Free CF
-$109.7M
52W Change
-50.8%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $559.5M in cash comfortably exceeding the $15.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$109.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -33.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $11.7M (2021) to $72.6M (2025), reflecting a 521% increase over the period.
With a beta above 1.5, BCYC tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, BCYC has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing BCYC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.